DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT01972542

CompletedPhase NA

The Usefulness of Postprandial Triglyceride for Assessment of Cardiovascular Risk

The Usefulness of Postprandial Triglyceride for Assessment of Cardiovascular Risk in Healthy People, Impaired Glucose Tolerance and Type 2 Diabetes

Asset

GLP-1 / incretin class catch-all

Listed sites

1

Recruiting sites

—

Enrollment

80

actual

Study population

Healthy volunteers, Prediabetes / glucose intolerance, Type 2 diabetes

Key I/E criterion

•HbA1c ≤10%

Primary endpoint

•Triglycerides, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01972542
Org study IDSNUBH-ENDO4

Timeline

Milestones

Study first posted2013-10-30estimated
Last update posted2015-10-27estimated
Study start2013-06 (month precision)
Primary completion2015-07actual (month precision)
Study completion2015-08actual (month precision)

Assets

Investigational agents

GLP-1 / incretin class catch-all

Study populations

Who this study enrolls

Healthy volunteersPrediabetes / glucose intoleranceType 2 diabetes

Eligibility

Who can enroll

Minimum age19 Years
Maximum age70 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

•age : 19 ~ 70 yrs
•Type 2 diabetes : HbA1c <10%
•Prediabetic state : HbA1c 5.7~6.4%

Exclusion criteria

•Type 1 diabetes, secondary diabetes
•dipeptidyl peptidase-4 -inhibitor, glucagon-like peptide-1 agonist, thiazolidinediones users
•Thyroid disease with abnormal thyroid function test
•Liver disease with abnormal liver function test
•severe kidney disease
•pregnant or lactating women
•current smoker
•severe obesity

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiometabolic biomarkers
1
Other (unclassified)
1

Cardiometabolic biomarkers

1 endpoint
Primary/protocol endpoint

Changes of Triglyceride

Time frame:8 hours

Triglycerides, change

change from baseline, improvement

LOINC 2571-8

Other (unclassified)

1 endpoint
Secondary/protocol endpoint/low confidence

Changes of incretin

Time frame:8 hours

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.